(PSTV) Plus Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PSTV) Plus Therapeutics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Plus Therapeutics, Inc. BCG Matrix is a company-specific tool for reviewing the portfolio across Stars, Cash Cows, Question Marks, and Dogs, helping with strategy, investment, and capital allocation decisions. The page already shows a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
0 approved products
Plus Therapeutics had 0 FDA-approved products at end-2025, so it had no Star franchise driving sales. The company remained clinical-stage, with revenue still tied to research, grants, or other non-commercial sources rather than marketed products. That means its BCG profile stayed in the question-mark zone, not the Star zone.
0 market-leading brands
Plus Therapeutics, Inc. had no marketed product with a dominant share in a large commercial market, so it had 0 Star brands. In FY2025, its value was still tied to clinical-stage pipeline assets, not proven commercial demand. The lead programs were still seeking clinical validation and physician adoption, which is not a BCG Star profile.
0 commercial CNS therapies
Plus Therapeutics had 0 commercial CNS therapies, so this was a pure development stage Stars case. Its lead program, Rhenium-186 NanoLiposome (RNL), was still in trials and had not reached broad market use or market leadership. Promotion spend was still R&D spend, with 2025 revenue still minimal versus development costs.
0 recurring product royalties
Plus Therapeutics, Inc. showed
0 recurring product royalties
, so there was no mature royalty stream from a sold or marketed product. Cash generation still depended on financing and clinical milestones, which is not Star behavior. In BCG terms, that makes this a weak fit for Star status because revenue was not compounding from a commercial base.- 0 recurring royalties
- No marketed product cash stream
- Funding tied to milestones
0 high-share growth franchises
End-2025, Plus Therapeutics, Inc. still looked like a Question Mark, not a Star: the pipeline had optionality, but no high-share growth franchise. The assets were still speculative, so value rested on future clinical or regulatory wins, not current market dominance.
In BCG terms, that means low share with uncertain growth, not a proven winner.
- Optionality drove value in 2025.
- No dominant franchise was visible.
- Assets remained speculative.
Plus Therapeutics Ends 2025 Without a Star Franchise
Plus Therapeutics, Inc. had no Stars at end-2025. It had 0 FDA-approved products, 0 marketed CNS therapies, and no dominant commercial franchise, so revenue did not come from a high-share growth product. Its value still depended on R&D and clinical milestones, not Star-level cash generation.
| Metric | FY2025 |
|---|---|
| FDA-approved products | 0 |
| Marketed products | 0 |
| Star franchises | 0 |
What is included in the product
Detailed Word Document
Plus Therapeutics’ BCG Matrix maps its pipeline to show where to invest, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page Plus Therapeutics, Inc. BCG Matrix that clarifies quadrant positioning and eases strategic decision-making.
Reference Sources
Provides a clear source trail for Plus Therapeutics, Inc., boosting credibility and helping investors verify key assumptions fast.
Cash Cows
0 cash cows
Plus Therapeutics had 0 cash cows because it had no mature, high-share, low-growth product to harvest. In its latest filings, the Company still reported no product sales and only early-stage pipeline assets, so nothing was generating steady excess cash. That meant there was nothing to milk for internal funding.
0 low-growth leaders
Plus Therapeutics had 0 cash cows: in FY2025 it had no approved, mature product in an established market with durable share. Its oncology assets were still in early-stage development, so the business depended on R&D spend, not stable product sales. Without a commercial franchise, mature-market economics like steady margins, repeat demand, and cash generation were still absent.
0 stable gross-margin franchises
Plus Therapeutics, Inc. had 0 stable gross-margin franchises because it had no commercial product to support operating leverage. With no recurring product sales, gross profit was not a meaningful source of cash, so there was no Cash Cow base to fund the business. In recent filings, revenue has remained tied to limited licensing and collaboration activity, not durable product margins.
0 dividend-supporting assets
Plus Therapeutics, Inc. had 0 dividend-supporting assets because it was still a clinical-stage biotech, not a cash-generating company. There was no free-cash-flow engine to cover dividends or debt service, so corporate funding still depended on equity or other capital-market raises.
That fits the model: biotech firms in development usually burn cash on trials, R&D, and approvals before they build stable operating cash flow. In FY2025, Plus Therapeutics still had no dividend capacity, so it was not a Cash Cow.
- Clinical-stage, not cash-rich
- No free cash flow for dividends
- Funding tied to capital markets
- High R&D spend, low cash generation
0 mature royalty annuities
By end-2025, Plus Therapeutics, Inc. had 0 mature royalty annuities, so it had no steady license income to cushion operations. Any partner deals were still development-stage and milestone-dependent, which means cash inflows stayed tied to trial progress and other binary events. That keeps cash flow uneven and raises funding risk.
- 0 mature royalty annuities
- Development-stage deals only
- Milestone-based cash flow
Plus Therapeutics Had No Cash Cows in FY2025
Plus Therapeutics, Inc. had 0 Cash Cows in FY2025. It still had no approved product, no steady product sales, and no durable free cash flow to fund operations. Cash inflow stayed tied to early-stage collaboration and milestone work, not mature market demand.
| Metric | FY2025 |
|---|---|
| Cash Cows | 0 |
| Product sales | None |
| Free cash flow | Negative |
Preview Before You Purchase
Plus Therapeutics, Inc. Reference Sources
This Plus Therapeutics, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No placeholders, no watermarks—just the complete, professionally formatted report. Once purchased, the full file is instantly available for download and use.
Dogs
2019 rebrand from Cytori
The July 2019 rebrand from Cytori Therapeutics to Plus Therapeutics was a reset of the legacy platform, not a commercial moat. As of FY2025, the company still lacked durable scale, with no evidence of a broad revenue engine to back the old identity shift. In BCG terms, Dogs fits a mature, low-share position that needs hard proof of demand, not a name change.
0 scaled commercial sales force
Plus Therapeutics has no marketed product revenue in its latest filings, so a scaled commercial sales force of 0 is rational. Without a commercial product, a large sales team would burn cash without near-term return. It also signals there is no mature, low-share business to defend.
Equity-funded operations
Plus Therapeutics, Inc. is still clinical-stage, so operations depend on outside capital rather than product cash in. In its latest filings, the Company still showed no commercial sales and ongoing research spending, which keeps cash burn ahead of operating inflow. That makes equity funding a structural weakness, because each raise can dilute shareholders when trials keep consuming cash.
Precommercial overhead
Plus Therapeutics, Inc. sits in a Dog-like spot because precommercial overhead keeps running while product sales are still absent. General and administrative costs, plus R&D, can drain cash fast when there is no marketed franchise to fund them, so the return on that spend stays low.
That is why this segment fits the classic Dog profile: cash outflow now, little operating leverage yet, and no near-term scale to offset fixed costs. In 2025/2026 filings, the key check is whether cash use is falling faster than overhead, or the drag stays heavy.
- Precommercial costs still hit cash.
- No marketed product means no offset.
- Low scale keeps returns weak.
- Watch cash burn and overhead trend.
R&D burn without sales
Plus Therapeutics, Inc. still fits Dogs: R&D spending supports pipeline work, but product sales have not yet covered operating costs, so cash burn stays high. The Company remains tied to clinical milestones, and until a win turns into revenue, dilution and financing risk stay elevated.
- High R&D, low near-term revenue
- Burn depends on clinical progress
- Funding need remains a key risk
Plus Therapeutics: No Revenue, Rising Burn, and Dilution Risk
Plus Therapeutics, Inc. is still a Dog: FY2025 shows no marketed product revenue, so R&D and G&A keep draining cash without offset. That leaves the Company dependent on equity or other outside funding, and dilution risk stays high until a product reaches scale.
| FY2025 | Signal |
|---|---|
| No product revenue | Weak share |
| R&D and G&A | Cash burn |
| External funding | Dilution risk |
Question Marks
Rhenium-186 NanoLiposome (R-186 NL)
Rhenium-186 NanoLiposome (R-186 NL) is Plus Therapeutics, Inc.’s lead asset and main growth option: a patented radiotherapy platform for hard-to-treat CNS cancers. It sits in the Question Mark bucket because it has high clinical upside, but by end-2025 it still needed proof in late-stage trials and regulatory conversion before it could scale.
Recurrent glioblastoma
Recurrent glioblastoma is a core target for Plus Therapeutics’ R-186 NL, but Plus still has little current share, so it fits the BCG "Question Mark" bucket. Glioblastoma remains highly unmet, with median overall survival of about 15 months in newly diagnosed patients and only about 5% five-year survival. That mix of big need and weak share means the case depends on clinical uptake and funding.
Leptomeningeal metastases
R-186 NL for leptomeningeal metastases fits a Question Mark: the market is tiny but severe, with leptomeningeal disease affecting about 5% of patients with solid tumors and median survival often only 3-6 months. Plus Therapeutics, Inc. had not yet built meaningful commercial share, so current returns were low. If R-186 NL wins approval and adoption, the upside could be large; if not, it stays a costly niche bet.
Pediatric brain and CNS cancers
Plus Therapeutics has positioned R-186 NL for pediatric brain and other CNS tumors, but this is still a Question Mark in the BCG grid because share was low at end-2025. In the U.S., pediatric CNS cancers are rare, with about 4,000 new cases a year, so orphan pricing and payer support can help if clinical data stay strong. The market can move fast, but adoption will hinge on proof of benefit and center-by-center uptake.
- Low share, high unmet need
- Orphan economics can lift uptake
NanoTx glioblastoma license
Plus Therapeutics’ NanoTx glioblastoma license fits Question Mark status because the asset is still in development and has no market sales yet. Glioblastoma remains a hard target, with about 15,000 U.S. cases a year and a 5-year survival rate near 7%, so the upside is real but uncertain. As of Plus Therapeutics’ latest 2025 filings, this program is still a capital-heavy bet, not a cash generator.
- Development-stage asset, no product revenue
- High unmet need, high trial risk
- Potential upside if clinical data improves
Plus Therapeutics’ High-Risk, High-Upside CNS Oncology Bets
Plus Therapeutics, Inc.’s Question Marks are R-186 NL and NanoTx-led CNS oncology programs: high unmet need, low share, and heavy trial risk. Glioblastoma still has about 15,000 U.S. cases a year and near 7% five-year survival, while leptomeningeal metastases affects about 5% of solid-tumor patients with 3-6 month median survival.
| Program | Why Question Mark |
|---|---|
| R-186 NL | High upside, low share |
| Glioblastoma | Big need, no scale yet |
| Leptomeningeal disease | Niche market, high risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.